Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study

被引：0

作者：

Arnold, Douglas ^{[1
,2
]}

Freeman, Leorah ^{[3
]}

Hartung, Hans-Peter ^{[4
,5
,6
,7
]}

Montalban, Xavier ^{[8
]}

Cohen, Jeffrey ^{[9
]}

Bar-Or, Amit ^{[10
,11
]}

Steinman, Lawrence ^{[12
]}

DeLuca, John ^{[13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[16
]}

机构：

[1] NeuroRx Res, Montreal, PQ, Canada

[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[3] Univ Texas Austin, Dell Med Sch, Austin, TX USA

[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany

[5] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[6] Med Univ Vienna, Dept Neurol, Vienna, Austria

[7] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic

[8] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[9] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

[10] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA USA

[11] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA

[12] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA USA

[13] Kessler Fdn, West Orange, NJ USA

[14] Rutgers New Jersey Med Sch, Dept Phys Med Rehabil & Neurol Neurosci, Newark, NJ USA

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1661/518

引用

页码：1050 / 1051

页数：2

共 50 条

[41] Final Data from Open-Label Extension Studies of Dalfampridine Extended Release Tablets in Multiple Sclerosis
Goodman, Andrew
Blight, Andrew
NEUROLOGY, 2012, 78
[42] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (vol 28, pg 1944, 2022)
不详
MULTIPLE SCLEROSIS JOURNAL, 2022,
[43] Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
Journal of Neurology, 2020, 267 : 2851 - 2864
[44] Evaluating No Evidence of Disease Activity (NEDA) in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod
Kappos, L.
Comi, G.
Selmaj, K. W.
Steinman, L.
Bar-Or, A.
Arnold, D. L.
Hartung, H. P.
Montalban, X.
Havrdova, E. K.
Pachai, C.
Sheffield, J. K.
Cheng, C. Y.
Silva, D.
Vaile, J.
Morello, J. P.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 11 - 12
[45] VISIONARY-MS Long-Term Extension: A Multicenter, Open-Label, Long-Term Extension Study of CNM-Au8 in Patients With Stable Relapsing Multiple Sclerosis
Barnett, Michael
Beadnall, Heidi
Klistorner, Alexander
Sergott, Robert
Greenberg, Benjamin
Rynders, Austin
Ho, Karen
Sepassi, Marjan
Evan, Jacob
Evan, Jeremy
McBride, Ryan
Hartford, Alan
Hotchkin, Michael
NEUROLOGY, 2024, 102 (12) : S12 - S13
[46] Five years of Ublituximab in relapsing multiple sclerosis: additional results from open-label extension of ULTIMATE I and II studies
Cree, Bruce A. C.
Fox, Edward
Hartung, Hans Peter
Alvarez, Enrique
Qian, Peiqing
Wray, Sibyl
Robertson, Derrick
Huang, Deren
Selmaj, Krzysztof
Wynn, Daniel
Mok, Koby
Hsu, Yanzhi
Xu, Yihuan
Rowland, Chris
Bodhinathan, Karthik
Sportelli, Peter
Parker, Jackie
Miskin, Hari
Steinman, Lawrence
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 348 - 349
[47] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Cohen, Stanley
Pablos, Jose L.
Zhang, Nan
Rizzo, Warren
Muller, Gerhard
Padmanaban, Devi
Kivitz, Alan
Matsumoto, Alan K.
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[48] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
Ashina, M.
Roos, C.
Ayer, D. W.
Ruff, D.
Krege, J. H.
Li, L. Q.
Komori, M.
HEADACHE, 2022, 62 : 113 - 114
[49] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Ashina, M.
Roos, C.
Ayer, D.
Ruff, D.
Krege, J.
Li, L. Q.
Komori, M.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[50] VILOXAZINE EXTENDED-RELEASE CAPSULES IN CHILDREN AND ADOLESCENTS WITH ADHD: FINAL RESULTS OF A LONG-TERM, PHASE 3, OPEN-LABEL EXTENSION STUDY
Findling, Robert L.
Waxmonsky, James G.
Katic, Alain
Liebowitz, Michael R.
Hull, Joseph T.
Fry, Nicholas
Maldonado-Cruz, Zulane
Yarullina, Ilmiya
Qin, Peibing
Rubin, Jonathan S.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S194 - S194

← 1 2 3 4 5 →